Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results84

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results41

Views

Views
July 202526
August 20250
September 20253
October 20257
November 20252
December 20252
January 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States18
Brazil11
United Kingdom5
Argentina3
Egypt1
Tunisia1
Turkey1
Venezuela1
 

Top cities views

Views
Anchorage1
Buenos Aires1
Caruaru1
Chebba1
Clifton1
Dallas1
Dunoon1
Duque de Caxias1
Formiga1
Fort Bragg1